Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

BACKGROUND: Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption, lichenoid reactions, erythroderma, and skin rash. D...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Maxillofac Plast Reconstr Surg
Hlavní autoři: Bombeccari, Gian Paolo, Garagiola, Umberto, Pallotti, Francesco, Rossi, Margherita, Porrini, Massimo, Giannì, Aldo Bruno, Spadari, Francesco
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5714941/
https://ncbi.nlm.nih.gov/pubmed/29230387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40902-017-0136-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky